SARS-Coronavirus-2 nucleocapsid protein measured in blood using a Simoa ultra-sensitive immunoassay differentiates COVID-19 infection with high clinical sensitivity - Shan, Dandan; Johnson, Joseph M; Fernandes, Syrena C.; Mendes, Muriel; Suib, Hannah; Holdridge, Marcella; Burke, Elaine M; Beauregard, Katie; Zhang, Ying; Cleary, Megan; Xu, Samantha; Yao, Xiao; et al. (medRxiv, 2020)
The COVID-19 pandemic continues to have an unprecedented impact on societies and economies worldwide. Despite rapid advances in diagnostic test development and scale-up, there remains an ongoing need for SARS-CoV-2 tests which are highly sensitive, specific, minimally invasive, cost-effective, and scalable for broad testing and surveillance. Here we report development of a highly sensitive single molecule array (Simoa) immunoassay on the automated HD-X platform for the detection of SARS-CoV-2 Nucleocapsid protein (N-protein) in venous and capillary blood (fingerstick). In pre-pandemic and clinical sample sets, the assay has 100% specificity and 97.4% sensitivity for serum / plasma samples. The limit of detection (LoD) estimated by titration of inactivated SARS-CoV-2 virus is 0.2 pg/ml, corresponding to 0.05 Median Tissue Culture Infectious Dose (TCID50) per ml, > 2000 times more sensitive than current EUA approved antigen tests. No cross-reactivity to other common respiratory viruses, including hCoV229E, hCoVOC43, hCoVNL63, Influenza A or Influenza B, was observed. We detected elevated N-protein concentrations in symptomatic, asymptomatic, and pre-symptomatic PCR+ individuals using capillary blood from a finger-stick collection device. The Simoa SARS-CoV-2 N-protein assay has the potential to detect COVID-19 infection via antigen in blood with performance characteristics similar to or better than molecular tests, while also enabling at home and point of care sample collection.One Sentence Summary SARS-CoV-2 nucleocapsid protein (N-protein) measured in serum, plasma, and dried blood spots (DBS) via ultrasensitive immunoassay can be used to differentiate PCR+ from PCR-patients, even if asymptomatic.Competing Interest StatementEmployees with institution marked as Quanterix Corporation are employees of Quanterix Corporation.Funding StatementThis work was partly funded through a Rapid Acceleration of Diagnostics (RADx) grant from the National Institutes of Health, awarded through the University of Massachusetts Medical School.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CTCH study: all patients and staff who participated in the study signed a consent form (families signed on behalf of residents). The consenting process was administered by the nursing home directly. U. Bonn: The study was approved by the Institutional Review board of the University Hospital Bonn (134/20). Patients were included after providing written informed consent. In COVID-19 patients who were not able to consent at the time of study enrollment, consent was obtained after recovery.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be made available upon written request submitted to the corresponding author.